🇺🇸 FDA
Patent

US 11890340

Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders

granted A61KA61K2039/505A61K31/7088

Quick answer

US patent 11890340 (Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2039/505, A61K31/7088, A61K31/711, A61K31/713